The world of small-cap health care investing is one of huge booms and major busts. However, equities.com's Small-Cap Stars, our proprietary list of small-cap companies with characteristics we've found to be most predictive of future success, helps you find those companies with a strong foundation that are best positioned to capitalize on future success.
Here are today's top-performing health care Small-Cap Stars as of noon on the east coast:
Boston Therapeutics Inc (BTHE)
Boston Therapeutics Inc gained 6.67% to $0.48 in morning trading today. Volume reached 22,200 by noon. The stock's average daily volume is 27,578 shares. Boston Therapeutics Inc has a 52-week high of $1.67 and a 52-week low of $0.15, and its 50-day SMA and 200-day SMA are $0.54 and $0.89 respectively.
Boston Therapeutics Inc is engaged in developing, manufacturing and commercializing of therapeutic drugs with a focus on complex carbohydrate chemistry to address diabetes and inflammatory diseases.
Iridex Corporation (IRIX)
Iridex Corporation gained 2.03% to $8.04 in morning trading today. Volume reached 1,146 by noon. The stock's average daily volume is 22,849 shares. Iridex Corporation has a 52-week high of $11.00 and a 52-week low of $5.72, its P/E ratio is 46.5, and its 50-day SMA and 200-day SMA are $8.06 and $8.73 respectively.
Iridex Corp along with its subsidiaries, is a provider of therapeutic based laser console, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology.
Navidea Biopharmaceuticals (NAVB)
Navidea Biopharmaceuticals gained 1.59% to $1.28 in morning trading today. Volume reached 171,238 by noon. The stock's average daily volume is 597,317 shares. Navidea Biopharmaceuticals has a 52-week high of $3.15 and a 52-week low of $1.11, and its 50-day SMA and 200-day SMA are $1.45 and $1.70 respectively.
Navidea Biopharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of precision diagnostics and radiopharmaceutical agent.
Provectus Biopharmaceuticals Inc. (PVCT)
Provectus Biopharmaceuticals Inc. gained 1.31% to $0.85 in morning trading today. Volume reached 64,133 by noon. The stock's average daily volume is 436,508 shares. Provectus Biopharmaceuticals Inc. has a 52-week high of $6.03 and a 52-week low of $0.30, and its 50-day SMA and 200-day SMA are $0.95 and $1.65 respectively.
Provectus Biopharmaceuticals Inc is a development-stage pharmaceutical company. It develops, licenses, and sells pharmaceutical products for oncology and dermatology indications.
Ampio Pharmaceuticals Inc. (AMPE)
Ampio Pharmaceuticals Inc. gained 0.92% to $6.57 in morning trading today. Volume reached 255,277 by noon. The stock's average daily volume is 547,067 shares. Ampio Pharmaceuticals Inc. has a 52-week high of $10.86 and a 52-week low of $5.07, and its 50-day SMA and 200-day SMA are $7.12 and $7.34 respectively.
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company, engaged in developing innovative, proprietary pharmaceutical drugs and diagnostic products to identify, treat and prevent human diseases including metabolic disorders, cancer etc.
Equities.com's Health Care Small-Cap Stars - Helping You Build a Healthier Portfolio
There's no crystal ball that will tell you what the outcome of this or that clinical trial is going to be. Even if there were, the one astonishingly wealthy person who owns it probably wouldn't share. But that doesn't mean that investing in the right small-cap health care companies can't pay dividends in the long term. While the future of a company's lead therapy may not be certain, most of its present fundamentals are. And while investing in the small-cap biotech market will always be hit-or-miss, investing in solidly built players should help boost that batting average.
Our Small-Cap Stars system uses a complex statistical regression to isolate those fundamental factors that previous success stories had in common and then identifies those small caps that are the most similar to that profile in the present.
For health care companies, we found that a high enterprise value, a strong value line beta, and a high rate of reinvestment were among the most indicative of a small-cap company's potential for success.
All data provided by QuoteMedia and was accurate as of 12:00 pm ET.